급성 심근경색 : 시장 인사이트, 역학 및 시장 예측(2036년)

Acute Myocardial Infarction (AMI) Insights and Trends

• According to DelveInsight's analysis, the AMI market size was found to be ~USD 1600 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• AMI is defined as myocardial cell death due to prolonged ischemia, with early changes such as glycogen depletion, myofibril relaxation, and sarcolemmal disruption occurring within 10-15 minutes of onset.
• Clinical presentation typically includes chest pain/pressure, often radiating to the left arm, jaw, neck, back, or upper abdomen, and may be accompanied by sweating, nausea, vomiting, or syncope.
• The widespread use of cardiac biomarkers (e.g., troponins) has significantly improved diagnostic accuracy, but also complicates trend analyses due to evolving thresholds and the detection of smaller infarctions.
• Enhanced biomarker sensitivity has led to better case detection, which may mask true declines in incidence and create an apparent reduction in mortality rates by identifying milder cases.
• The current treatment landscape includes antiplatelets, anticoagulants, beta-blockers, vasodilators, lipid-lowering agents, ACE inhibitors, ARBs, and calcium channel blockers, forming the backbone of AMI management.
• The approval of LODOCO by AGEPHA Pharma marks a shift toward targeting residual inflammatory risk, offering a novel mechanism to reduce cardiovascular events.
• Despite advances in prevention and treatment, AMI remains a leading cause of morbidity and mortality in the United States.
• Whereas the emerging AMI pipeline is steadily evolving, a number of late- and mid-stage assets such as Selatogrel, dapagliflozin, FDY-5301, Zalunfiban (RUC 4) are currently being evaluated for their potential to improve clinical outcomes.

Acute Myocardial Infarction (AMI) Market Size and Forecast in the 7MM

• 2025 AMI Market Size: ~USD 1,600 million
• 2036 Projected AMI Market Size: ~USD 6,000 million
• AMI Growth Rate (2026-2036): 13% CAGR

DelveInsight's 'Acute Myocardial Infarction (AMI) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the AMI, historical and forecasted epidemiology, as well as the AMI market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Acute Myocardial Infarction (AMI) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates AMI patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in AMI and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Acute Myocardial Infarction (AMI) Market

Expanding Therapeutic Landscape and Innovation

The AMI market is witnessing rapid innovation, with emerging therapies targeting residual cardiovascular risk, inflammation, and plaque stabilization. Key pipeline assets from companies such as Amgen, Novo Nordisk, and Bristol Myers Squibb are expected to transform treatment paradigms during the forecast period.

Growing Focus on Preventive and Long-term Management

There is an increasing emphasis on secondary prevention strategies, including lipid-lowering therapies, antiplatelets, and anti-inflammatory agents, to reduce recurrent cardiovascular events, thereby expanding the long-term treatment market.

Rising Healthcare Expenditure and Awareness

Increasing healthcare spending, improved access to advanced treatments, and growing awareness of cardiovascular diseases across the 7MM are supporting market expansion, particularly in developed regions.

Acute Myocardial Infarction (AMI) Understanding and Treatment Algorithm

Acute Myocardial Infarction (AMI) Overview and Diagnosis

AMI is the ischemic necrosis of myocardial tissue, most commonly caused by coronary artery disease and acute plaque rupture with thrombosis. It typically presents as part of acute coronary syndrome (ACS) with symptoms such as chest pain, dyspnea, nausea, and diaphoresis. Myocardial Infarction is broadly classified into STEMI (ST-Elevation Myocardial Infarction) and NSTEMI (Non-ST-Elevation Myocardial Infarction), as well as Type 1 MI (atherothrombotic) and Type 2 MI (oxygen supply-demand mismatch). Despite advances in care, AMI remains a leading cause of mortality globally, driven by key risk factors including hypertension, diabetes, smoking, and dyslipidemia.

Acute Myocardial Infarction (AMI) Diagnosis

Diagnosis of MI is based on a combination of clinical presentation, electrocardiography (ECG) findings, and elevation of cardiac biomarkers, particularly troponins, which are the most sensitive and specific indicators of myocardial injury. ECG plays a critical role in differentiating STEMI vs. NSTEMI and guiding urgent treatment decisions. Additional tools, such as echocardiography, help identify wall motion abnormalities, while coronary angiography provides a definitive diagnosis and enables revascularization. Early and accurate diagnosis is essential for timely reperfusion therapy and reducing complications.

Acute Myocardial Infarction (AMI) Treatment

The treatment of AMI centers on rapid symptom relief, early ECG diagnosis, and prompt reperfusion. Initial therapy includes nitroglycerin, morphine, immediate antiplatelet therapy (aspirin +- P2Y12 inhibitors), and anticoagulation. In STEMI, primary PCI (within 60-90 min) is preferred, while fibrinolysis with agents such as tenecteplase is used if PCI is not available.

Long-term management focuses on reducing mortality and recurrence with dual antiplatelet therapy (DAPT), B-blockers, ACE inhibitors/ARBs, and statins. In addition to these standard therapies, select approved agents such as colchicine have demonstrated benefit in reducing cardiovascular events through anti-inflammatory mechanisms, while evolocumab provides intensive LDL-C lowering for high-risk patients, further supporting secondary prevention. Nitrates help relieve ischemia, and calcium channel blockers are alternatives when B-blockers are contraindicated.

Acute Myocardial Infarction (AMI) Unmet Needs

The section "unmet needs of Acute Myocardial Infarction (AMI)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Treatment options for reperfusion injury

2. Emergency care and prevention

3. Use of a combination of cardiovascular endpoints

4. Lack of data on longitudinal medication use

5. Misdiagnosis, along with the need for faster diagnosis and treatment of AMI, and others.....

Acute Myocardial Infarction (AMI) Epidemiology

Key Findings from Acute Myocardial Infarction (AMI) Epidemiological Analysis and Forecast

• According to DelveInsight estimates, approximately ~1,500,000 incident cases of AMI were reported across the 7MM in 2025, with the highest number of cases in the US.
• AMI is more common in men than women, as there were 950,000 incident cases for males and 550,000 cases for females in the 7MM in 2025.
• Among the EU4 and the UK, Germany reported the highest number of incident cases of AMI in 2025, while Spain had the lowest.
• According to estimates, there were ~510,000 cases of STEMI and ~990,000 cases of NSTEMI in the 7MM in 2025.
• According to epidemiological estimates, STEMI accounts for a smaller proportion of total acute myocardial infarction cases compared to NSTEMI; however, STEMI is associated with higher immediate mortality and requires urgent reperfusion therapy, making it a critical focus of acute care management.

Acute Myocardial Infarction Drug Analysis & Competitive Landscape

The AMI drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the AMI treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the AMI therapeutics market.

Approved Therapies for Acute Myocardial Infarction (AMI)

Colchicine (LODOCO): AGEPHA Pharma

LODOCO, developed by AGEPHA Pharma, is an anti-inflammatory therapy approved to reduce the risk of recurrent cardiovascular events. In AMI, it is positioned as an adjunctive treatment in the post-myocardial Infarction setting, targeting residual inflammation to help lower the risk of subsequent events.

Tenecteplase (TNKase): Genentech

Tenecteplase is a fibrinolytic therapy indicated for AMI, used to achieve rapid reperfusion by dissolving coronary thrombi. Its longer half-life and single-bolus administration enable faster and more convenient treatment compared to alteplase, making it a key option when primary Percutaneous Coronary Intervention is not readily available.

Acute Myocardial Infarction (AMI) Pipeline Analysis

Selatogrel (ACT-246475): Idorsia Pharmaceuticals and Viatris

Selatogrel is a potent, fast-acting, reversible, and highly selective P2Y12 inhibitor being developed for the treatment of patients with a history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector). This novel, self-administered emergency agent has the potential to protect the heart muscle in the very early phase of an AMI in the crucial time between symptom onset and first medical attention, to treat the ongoing AMI, and prevent early death.

Dutogliptin (REC-01): Recardio

Dutogliptin, developed by Recardio, is a potent and selective DPP4 inhibitor. Dutogliptin is administered via SC injection; the protein belongs to the class of enzyme inhibitors called gliptins or DPP-IV inhibitors. The combination of G-CSF with dutogliptin significantly enhanced survival and reduced infarct size in the preclinical model. Once the diagnosis of AMI is confirmed and percutaneous intervention and stent implantation are completed, the patient receives or can self-administer daily SC injection of dutogliptin for 2 weeks in co-administration with G-CSF for 5 days.

Acute Myocardial Infarction (AMI) Key Players, Market Leaders, and Emerging Companies

• AGEPHA Pharma
• Genentech
• Amgen
• Merck
• Regeneron and Sanofi
• Idorsia Pharmaceuticals and Viatris
• Recardio
• AstraZeneca
• Faraday Pharmaceuticals
• Novo Nordisk, and others

Acute Myocardial Infarction (AMI) Drug Updates

• In June 2024, Faraday Pharmaceuticals announced the completion of enrollment in its ongoing pivotal Phase III Iocyte AMI-3 trial of FDY-5301.
• In February 2024, Idorsia announced that the company has entered into agreements for a significant global research and development collaboration with Viatris for the global development and commercialization of two Phase III assets - selatogrel and cenerimod - for an upfront payment of USD 350 million, potential development and regulatory milestone payments, and certain contingent payments of additional sales milestone payments and tiered royalties from mid-single- to low double-digit percentage on annual net sales.
• In July 2020, AstraZeneca announced that Farxiga (dapagliflozin) was granted Fast Track Designation by the US FDA for the treatment of heart failure following AMI, supporting its development in the Phase III DAPA-MI trial using an innovative registry-based study design to evaluate its potential in reducing cardiovascular death and heart failure outcomes post-MI.

Drug Class Insights

Acute Myocardial Infarction (AMI) Market Outlook

The AMI market is undergoing a gradual transformation following decades of reliance on reperfusion strategies and conventional antithrombotic therapies. While rapid intervention through PCI and thrombolytics remains the cornerstone of acute management, the expanding use of adjunctive and preventive therapies such as tenecteplase, colchicine, evolocumab, alirocumab, and vorapaxar reflects a shift toward comprehensive cardiovascular risk reduction. These therapies highlight the growing focus on addressing residual thrombotic, inflammatory, and lipid-driven risk, supporting a transition toward more mechanism-driven and long-term disease management in AMI.

With the advancement of targeted and novel therapies such as Selatogrel, Dutogliptin, Dapagliflozin, FDY-5301, Ziltivekimab, Milvexian, and Olpasiran, the AMI treatment landscape is evolving like other cardiovascular and metabolic diseases, where early innovation in targeted mechanisms is expected to catalyze broader therapeutic expansion. These emerging agents aim to address unmet needs in acute thrombosis management, inflammation control, and long-term risk reduction, thereby expanding the therapeutic scope beyond traditional approaches.

The United States continues to represent the largest AMI market, driven by high disease burden, advanced healthcare infrastructure, widespread access to PCI, and rapid adoption of novel therapies, compared with EU4, the United Kingdom, and Japan. Overall, the introduction of first-in-class and mechanism-driven therapies, along with improvements in early diagnosis and increasing awareness of secondary prevention, is expected to drive steady growth in the 7MM AMI market from 2022 to 2036, with strong commercial implications for both marketed products and emerging pipelines.

• The United States is expected to account for the largest market share of AMI among the 7MM, with projected significant growth through 2036.
• The AMI treatment landscape is evolving as the focus expands from acute reperfusion to long-term risk management, with lipid-lowering and anti-inflammatory therapies driving adoption.
• Regional market dynamics indicate that the US leads in revenue, while Japan and EU markets demonstrate steady growth, supported by improving access to advanced therapies and increasing awareness.
• Among available therapies, agents such as evolocumab are expected to generate significant revenue, particularly in the secondary prevention setting.
• The entry of mid- to late-stage candidates such as Selatogrel, Milvexian, and Olpasiran is expected to intensify competition and expand treatment options in the AMI landscape during the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Acute Myocardial Infarction (AMI) (2022-2036 Forecast)

The AMI treatment landscape comprises antithrombotic agents, cardioprotective drugs, and emerging targeted therapies, each addressing different aspects of thrombosis, ischemia, and post-MI remodeling.

• Antithrombotic agents: Include antiplatelets (e.g., aspirin, ticagrelor) and anticoagulants (e.g., heparins, bivalirudin), which form the backbone of AMI management by preventing thrombus formation and supporting reperfusion strategies such as PCI or fibrinolysis.
• Cardioprotective therapies: Include B-blockers, ACE inhibitors/ARBs, statins, and vasodilators, which reduce myocardial workload, limit infarct size, prevent adverse remodeling, and improve long-term survival following MI.
• Emerging therapies: Pipeline agents such as selatogrel and dutogliptin, along with cardiometabolic drugs like dapagliflozin, are being explored for early intervention, cardioprotection, and post- myocardial infarction remodeling benefits.

Overall, antithrombotic and cardioprotective drugs define the current standard of care, while novel targeted and cardiometabolic therapies are expected to drive future innovation in the AMI treatment landscape.

Acute Myocardial Infarction (AMI) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the AMI drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in AMI is expected to vary across acute reperfusion agents, antithrombotics, lipid-lowering therapies, and emerging targeted agents. Established therapies such as tenecteplase are anticipated to maintain strong and immediate uptake due to their critical role in rapid reperfusion, particularly in settings where timely PCI is not feasible. In contrast, recently approved or expanding therapies such as colchicine, evolocumab, and alirocumab are expected to demonstrate moderate but progressive uptake, supported by their targeted mechanisms, growing clinical evidence, and increasing physician focus on residual cardiovascular risk reduction in post-MI patients. Their adoption is likely to be driven by the limitations of standard therapies in preventing recurrent events and the need for improved long-term outcomes.

In comparison, next-generation targeted therapies such as Selatogrel, Milvexian, Ziltivekimab, and Olpasiran are anticipated to show gradual but steady uptake as clinical evidence expands and these agents are progressively incorporated into treatment algorithms addressing thrombosis, inflammation, and lipid-mediated risk. Their future adoption will depend on demonstrated clinical benefit, safety profiles, and positioning within both acute and secondary prevention settings.

Detailed insights into emerging therapies' drug uptake are included in the report.

Acute Myocardial Infarction (AMI) Therapies Price Scenario & Trends

Pricing and analogue assessment of AMI therapies highlight evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Acute Myocardial Infarction (AMI) Approved Drugs

Evolocumab is administered at a dose of 140 mg every two weeks or 420 mg once monthly for patients at high cardiovascular risk, including those with a history of acute myocardial infarction. The list price was initially reported at approximately USD 14,100 annually, later reduced to around USD 5,850 per year, translating to an estimated annual therapy cost of USD 5,850.

Further details are provided in the final report....

Industry Experts and Physician Views for Acute Myocardial Infarction (AMI)

To keep up with AMI market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the AMI emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in AMI, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as the Baylor Scott and White Research Institute in Dallas, Women's Hospital and Harvard Medical School, and Uppsala University, etc. were contacted. Their opinion helps understand and validate current and emerging AMI therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in AMI.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of AMI, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of AMI, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the AMI market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM AMI market.

Report Insights

• Acute Myocardial Infarction (AMI) Patient Population Forecast
• Acute Myocardial Infarction (AMI) Therapeutics Market Size
• Acute Myocardial Infarction (AMI) Pipeline Analysis
• Acute Myocardial Infarction (AMI) Market Size and Trends
• Acute Myocardial Infarction (AMI) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Acute Myocardial Infarction (AMI) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Acute Myocardial Infarction (AMI) Treatment Addressable Market (TAM)
• Acute Myocardial Infarction (AMI) Competitive Landscape
• Acute Myocardial Infarction (AMI) Major Companies Insights
• Acute Myocardial Infarction (AMI) Price Trends and Analogue Assessment
• Acute Myocardial Infarction (AMI) Therapies Drug Adoption/Uptake
• Acute Myocardial Infarction (AMI) Therapies Peak Patient Share Analysis

Report Assessment

• Acute Myocardial Infarction (AMI) Current Treatment Practices
• Acute Myocardial Infarction (AMI) Unmet Needs
• Acute Myocardial Infarction (AMI) Clinical Development Analysis
• Acute Myocardial Infarction (AMI) Emerging Drugs Product Profiles
• Acute Myocardial Infarction (AMI) Market Attractiveness
• Acute Myocardial Infarction (AMI) Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the AMI market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of AMI?
• What are the disease risks, burdens, and unmet needs of AMI? What will be the growth opportunities across the 7MM concerning the patient population with AMI?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of AMI? What are the current guidelines for treating AMI in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the AMI market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of . Acute Myocardial Infarction (AMI)

6. Acute Myocardial Infarction (AMI) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of AMI by Therapies (%) in the 7MM in 2025
• 6.3. Market Share of AMI by Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Acute Myocardial Infarction (AMI)

• 7.1. Introduction
• 7.2. Risk Factors
• 7.3. Pathophysiology
• 7.4. Clinical Classification of Myocardial Infarction
  • 7.4.1. Type 1
  • 7.4.2. Type 2
  • 7.4.3. Type 2 and myocardial injury
  • 7.4.4. Type 3
  • 7.4.5. Type 4a: Myocardial Infarction Associated With Percutaneous Coronary Intervention
  • 7.4.6. Type 4b: Stent/Scaffold Thrombosis Associated With Percutaneous Coronary Intervention
  • 7.4.7. Type 4c: Restenosis Associated With Percutaneous Coronary Intervention
  • 7.4.8. Type 5: Myocardial Infarction Associated With Coronary Artery Bypass Grafting
• 7.5. Diagnosis
• 7.6. Biomarkers
  • 7.6.1. Biomarkers Originated From Myocardial Tissues
  • 7.6.2. Biomarkers Induced by MI Incidence
  • 7.6.3. Biomarkers Preexisted Before MI Occurred
• 7.7. Definition of a Prior MI
  • 7.7.1. Recurrent MI
  • 7.7.2. Reinfarction
  • 7.7.3. Peri-procedural MI
• 7.8. WHO definition and diagnostic criteria of MI
  • 7.8.1. Category A definition and Diagnostic Criteria of MI
  • 7.8.2. Category B definition and diagnostic criteria of MI if the requirements for diagnostic tests in Category A (above) Have Not Been Met
  • 7.8.3. Category C definition and diagnostic criteria of probable MI
  • 7.8.4. Fourth Universal Definition of Myocardial Infarction
• 7.9. Treatment Algorithm
  • 7.9.1. Antiplatelet agents
  • 7.9.2. Anticoagulant agents
• 7.10. Treatment Guidelines
• 7.11. AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines: 2022
• 7.12. NICE Guidelines for Acute Coronary Syndromes: 2020
• 7.13. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation: 2017
• 7.14. ESC Guidelines for the Management of Acute Coronary Syndromes (ACS): 2024
• 7.15. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
• 7.16. Guideline Adherence and Longterm Clinical Outcomes in Patients with AMI in Japan

8. Epidemiology and Patient Population of Acute Myocardial Infarction (AMI)

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Incident Cases of AMI in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of AMI in the United States
  • 8.4.3. Type-specific Incident Cases of AMI in the United States
  • 8.4.4. Gender-specific Incident Cases of AMI in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of AMI in EU4 and the UK
  • 8.5.2. Type-specific Incident Cases of AMI in EU4 and the UK
  • 8.5.3. Gender-specific Incident Cases of AMI in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of AMI in Japan
  • 8.6.2. Type-specific Incident Cases of AMI in Japan
  • 8.6.3. Gender-specific Incident Cases of AMI in Japan

9. Patient Journey of Acute Myocardial Infarction (AMI)

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Acute Myocardial Infarction (AMI)
• 10.2. LODOCO (colchicine): AGEPHA Pharma
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst's View
• 10.3. TNKase (tenecteplase): Genentech
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Summary of Pivotal Trials
  • 10.3.5. Analyst's View
• 10.4. REPATHA (evolocumab): Amgen
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Summary of Pivotal Trials
  • 10.4.5. Analyst's View
• 10.5. ZONTIVITY (vorapaxar): Merck
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental Activity
  • 10.5.4. Summary of Pivotal Trials
  • 10.5.5. Analyst's View
• 10.6. PRALUENT (alirocumab): Regeneron and Sanofi
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Summary of Pivotal Trials
  • 10.6.5. Analyst's View
• 10.7. INSPRA (eplerenone): Pfizer
  • 10.7.1. Product description
  • 10.7.2. Regulatory milestones
  • 10.7.3. Other Developmental Activities
  • 10.7.4. Summary of Pivotal Trials
  • 10.7.5. Analyst's View
• 10.8. PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
  • 10.8.1. Product description
  • 10.8.2. Regulatory milestones
  • 10.8.3. Other developmental activities
  • 10.8.4. Summary of Pivotal Trials
  • 10.8.5. Analyst's View
• 10.9. BRILINTA/BRILIQUE (ticagrelor): AstraZeneca
  • 10.9.1. Product description
  • 10.9.2. Regulatory milestones
  • 10.9.3. Other developmental activities
  • 10.9.4. Summary of Pivotal Trials
  • 10.9.5. Analyst's View
• 10.10. EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
  • 10.10.1. Product description
  • 10.10.2. Regulatory milestones
  • 10.10.3. Other development activity
  • 10.10.4. Summary of Pivotal Trials
  • 10.10.5. Analyst's View
• 10.11. ATACAND (candesartan): AstraZeneca/Takeda
  • 10.11.1. Product description
  • 10.11.2. Regulatory milestones
  • 10.11.3. Other development activity
  • 10.11.4. Summary of Pivotal Trials
  • 10.11.5. Analyst's View
• 10.12. DIOVAN (valsartan): Novartis
  • 10.12.1. Product description
  • 10.12.2. Regulatory milestones
  • 10.12.3. Other development activity
  • 10.12.4. Summary of Pivotal Trials
  • 10.12.5. Analyst's View

11. Emerging Therapies

• 11.1. Competitive Landscape: Emerging Therapies
• 11.2. Selatogrel (ACT-246475): Idorsia Pharmaceuticals and Viatris
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst View
• 11.3. Dutogliptin: Recardio
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst View
• 11.4. FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
  • 11.4.4. Safety and efficacy
  • 11.4.5. Analyst View
• 11.5. FDY-5301: Faraday Pharmaceuticals
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activity
  • 11.5.3. Clinical Development
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Analyst View
• 11.6. Zalunfiban (RUC 4): CeleCor Therapeutics
  • 11.6.1. Product Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Safety and Efficacy
  • 11.6.5. Analyst View
• 11.7. Ziltivekimab: Novo Nordisk
  • 11.7.1. Product Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Analyst View
• 11.8. Milvexian: Bristol Myers Squibb and Johnson & Johnson Innovative Medicine
  • 11.8.1. Product Description
  • 11.8.2. Other Developmental Activities
  • 11.8.3. Clinical Development
  • 11.8.4. Analyst View
• 11.9. ProtheraCytes: CellProthera and BioCardia
  • 11.9.1. Product Description
  • 11.9.2. Other Developmental Activities
  • 11.9.3. Clinical Development
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Analyst View
• 11.10. KAND567: Kancera
  • 11.10.1. Product Description
  • 11.10.2. Other Developmental Activities
  • 11.10.3. Clinical Development
  • 11.10.4. Safety and Efficacy
  • 11.10.4. Analyst View
• 11.11. Olpasiran (AMG 890): Amgen and Arrowhead Pharmaceuticals
  • 11.11.1. Product Description
  • 11.11.2. Other Developmental Activities
  • 11.11.3. Clinical Development
  • 11.11.4. Safety and Efficacy
  • 11.11.4. Analyst View

Continued emerging therapies will be provided in the final report.

12. Acute Myocardial Infarction (AMI): Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
• 12.5. Total Market Size of AMI in the 7MM
• 12.6. United States Market Size
  • 12.6.1. Total Market Size of AMI in the United States
  • 12.6.2. Market Size of AMI by Therapies in the United States
• 12.7. EU4 and the UK Market Size
  • 12.7.1. Total Market Size of AMI in EU4 and the UK
  • 12.7.2. Market Size of AMI by Therapies in EU4 and the UK
• 12.8. Japan Market Size
  • 12.8.1. Total Market Size of AMI in Japan
  • 12.8.2. Market Size of AMI by Therapies in Japan

13. Unmet Needs of Acute Myocardial Infarction (AMI)

14. SWOT Analysis of Acute Myocardial Infarction (AMI)

15. KOL Views of Acute Myocardial Infarction (AMI)

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Acute Myocardial Infarction (AMI)

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
• 16.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. Reimbursement Scenario and Key HTA Decisions in AMI

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight